Aligos Therapeutics Aktie

Aligos has completed recruitment for both parts of the phase‑2 B‑SUPREME study of pevifoscorvir sodium in chronic hepatitis B (131 HBeAg‑positive in part 1a, 114 HBeAg‑negative in part 2a). The larger participant number in part 1a made a second interim sample‑size analysis unnecessary. The stock rose 13% on the news last week but is down 29% year‑to‑date; the company has a market capitalization of USD 41 million and more cash than debt. Key safety and efficacy data are expected in late Q3 2027. » More on de.investing.com

Aligos Therapeutics received an upfront payment of $25 million from Xiamen Amoytop for an exclusive license to Pevifoscorvir sodium for the treatment of chronic HBV infections in Greater China. In addition, up to $420 million in milestone payments and tiered royalties in the high single-digit percentage range were agreed. The payment is likely to extend the cash runway into the fourth quarter of 2026, while Aligos retains commercial and development rights outside Greater China and the right to conduct clinical trials in the region. The announcement drove the share price up nearly 20% in after-hours trading. » More on de.investing.com

Aligos Therapeutics granted an exclusive license for pevifoscorvir sodium to Xiamen Amoytop Biotech for Greater China and received a $25 million upfront payment. The deal includes up to $420 million in milestone payments and tiered royalties. Aligos retains rights for the U.S., Europe, South Korea, Japan and other markets, may run studies in Greater China, and Amoytop will fund the program there. The transaction is expected to extend Aligos’ cash runway into Q4 2026 and prompted a roughly 20% share price increase. » More on de.investing.com